Streptococcus pneumoniae serotypes 6B and 6A are important causes of infections, yet only 6B is included in current vaccines. It is, therefore, crucial to evaluate whether functional antibodies are produced against both types after vaccination. Concentration and opsonophagocytic activity (OPA) of antibodies to 6B and 6A polysaccharides were determined in serum samples from infants immunized with 3 different pneumococcal conjugate vaccines containing serotype 6B. In all vaccine groups, a significant correlation was found between the anti-6B and -6A antibody concentration and OPA. However, OPA to the vaccine serotype was detectable more commonly than OPA to the cross-reactive type. Furthermore, 5%-15% of the serum samples showed high OPA against the 6B but not the 6A strain. On average, 2-6 times more anti-6B antibodies were needed for 50% opsonophagocytic killing of the type 6A than the type 6B strain. Although pneumococcal type 6B conjugate vaccines elicit antibodies that cross-react with type 6A, not all anti-6B antibodies are functionally cross-reactive.
cross-reactive antibodies to 6A. There is evidence from previous studies that vaccines containing 6B are not always able to induce functional antibodies to the cross-reactive serotype [4, 5] . To study the cross-reactions, we evaluated the concentration and opsonophagocytic activity (OPA) of serum IgG antibodies to pneumococcal serotypes 6B and 6A in the serum samples of infants immunized with experimental lots of 3 conjugate vaccines against Streptococcus pneumoniae.
Materials and Methods
PncCRM (Wyeth-Lederle), a heptavalent pneumococcal conjugate vaccine, contains PSs 4, 6B, 9V, 14, 19F, and 23F and oligosaccharide 18C conjugated to variant diphtheria toxin CRM 197 . The tetravalent conjugate vaccines PncD and PncT (both from Aventis Pasteur) contain PSs 6B, 14, 19F, and 23F conjugated to diphtheria (PncD) or tetanus toxoid (PncT). Pneumovax (Aventis Pasteur) and PNU-IMMUNE (Wyeth-Lederle) are commercial 23-valent pneumococcal PS (PncPS) vaccines.
At ages 2, 4, and 6 months, Finnish infants were immunized in 2 consecutive trials with one of the pneumococcal conjugate vaccines: PncCRM ( ), PncD ( ), or PncT ( measured by EIA, as described elsewhere [6] . Antibody levels to 6B are given as micrograms per milliliter, as calculated on the basis of the officially assigned IgG values of the 89-SF reference serum. Because no official values were available for 6A, 10 U/mL was assigned as the anti-6A IgG concentration in 89-SF.
S. pneumoniae of serotypes 6A (reference strain from the World Health Organization collaborating Center for Reference and Research on Streptococci) and 6B (reference strain from the Centers for Disease Control and Prevention) were grown as described elsewhere [7] . In some experiments, additional strains of types 6A and 6B from American Type Culture Collection were used. OPA of serum antibodies was determined by measuring the killing of live pneumococci by fresh human polymorphonuclear leukocytes in the presence of antibody and complement [8] .
Statistical comparisons were done using log-transformed data in analysis of variance, independent t test, paired t test, and Pearson's correlation analysis. Yates's corrected x 2 test or Fisher's exact test was used to compare the number of infants with detectable (titer у8) or undetectable (titer !8) OPAs.
Results
At 7 months, after the primary immunizations with 6B-containing pneumococcal conjugate vaccines, infants had moderate anti-6B antibody concentrations and OPAs, which decreased significantly ( to ) between the ages of 7 and P ! .05 P p .001 14 months in all vaccine groups, except for the IgG concentration in the PncT group (figure 1). By contrast, the concentrations of anti-6A antibodies increased during the same period ( to ). Anti-6A OPAs were low at 7 and 14 P ! .05 P p .001 months. In every vaccine group, the OPA was significantly higher to 6B than to 6A strains after primary vaccinations ( ). Booster doses of PncPS or conjugate vaccines in-P ! .001 creased ( to ) the anti-6B and -6A concentra-P ! .05 P p .001 tions and OPAs. Still, OPAs were higher to serotype 6B than to 6A strains ( to ). PncCRM was superior to P ! .05 P p .001 the other vaccines in inducing a functional antibody response to the vaccine serotype 6B and to the cross-reactive type 6A (figure 1).
Correlations between anti-6B and -6A antibody concentration and OPAs against 6B and 6A strains were significant at all ages in every vaccine group (figure 2). Despite the relatively good correlations, there were several serum samples that had high anti-6B antibody concentrations but low or undetectable anti-6A concentrations ( figure 2, upper panels) . Furthermore, the OPAs were detectable (у8) more commonly to 6B than to 6A ( figure 2, lower panels) ; the difference between the serotypes was significant at all ages in every vaccine group ( to P ! .01 ), except in the PncCRM group after the conjugate P p .001 booster. In each group, 5%-15% of the serum samples had high OPAs to 6B (1100) but no OPA to 6A (!8) strain. None of the serum samples showed the opposite. To confirm this observation, part of these serum samples ( ) were tested with an n p 13 additional pair of type 6B and 6A strains. Again, none of the serum samples had OPAs to the 6A strain, whereas all 13 serum samples had OPA titer of у100 to the 6B strain.
The anti-6B IgG concentration correlated strongly with the OPA against the 6B strain in all vaccine and age groups (r p -.93; ; data not shown). The correlation between .62 P ! .001 anti-6A concentration and OPA against the 6A strain was mostly significant but not as strong ( -.89; to r p .15 P ! .20 ). Likewise, there was less correlation between the anti-P p .001 6B concentration and OPA against the strain type 6A (r p -.68; to ). No vaccine-specific differences .16 P ! .20 P p .001 could be found (data not shown). Of the serum samples having у1 mg/mL of anti-6B antibodies, a substantial proportion had no anti-6A OPA at 7 (66%-88%) and 14 (73%-93%) months. By contrast, after children were administered a booster dose of PncCRM, only 14% of their serum samples having у1 mg/mL of anti-6B had no OPA to 6A strain, compared with 58% for infants given booster doses of PncD ( ). After a booster P ! .01 dose of PncPS, 37%, 70%, and 67% in the PncCRM, PncD, and PncT groups, respectively, with у1 mg/mL of anti-6B had no OPA to 6A strain, and there were significant differences between the PncCRM group and the other 2 groups ( ). P ! .05 This reflects the higher immune response against type 6B in the PncCRM groups after boosting (figure 1). The respective percentages of serum samples with у1 mg/mL of anti-6B but no OPA to 6B strain were significantly lower ( to P ! .05 P p ): 2%-6% at 7 months, 16%-35% at 14 months, 0%-4% .001 after booster of conjugate vaccine, and 0%-11% after booster of PncPS.
On average, 2-6 times higher concentrations of anti-6B antibodies were required for 50% opsonophagocytic killing of type 6A (0.045-0.252 mg) than type 6B (0.016-0.068 mg) bacteria, depending on the vaccine. The difference was significant in all groups ( to ), with the exception of children P ! .05 P p .001 primed with and given booster doses of PncD ( ). P p .065
Discussion
The three 6B-containing experimental conjugate vaccines used in this study elicited functional, cross-reactive antibodies to pneumococcal serotypes 6B and 6A, but the quality of antibodies against the 2 serotypes differed. Vaccination generally induced lower functional activity of antibodies to 6A than to 6B. Several serum samples that showed good functional activity against 6B strains had no activity against 6A strains, and no serum sample showed the opposite. These results are in agreement with studies reporting some, though not perfect, in vitro cross-reactions [1, 4, 5] and in vivo cross-protection [9] [10] [11] [12] between the 2 types of serogroup 6.
Differences in the kinetics of anti-6B and -6A antibody concentration and OPA suggest that immunization with 6B-containing vaccines induces a response more efficiently to type 6B than to type 6A. The anti-6B antibody concentration and OPAs were moderate in most children after primary immunizations, followed by a significant decrease between ages 7 and 14 months, the period without vaccination. Meanwhile, no decrease in anti-6A OPA and an increase in anti-6A concentration were seen, which indicates that the kinetics of anti-6A formation were less dependent on vaccination than were the kinetics of anti-6B formation.
The chemical composition of group 6 pneumococcal PSs is identical, except for the rhamnopyranosylrribitol linkage: 6A has 1r3 linkage, whereas 6B has 1r4 linkage [1, 2] . This linkage has not been considered to be an immunodominant part of the tetrasaccharide repeating unit of group 6 PSs. According to this study, part of the antibodies seem to be specific to this nonidentical epitope, as suggested by the presence of serum samples lacking activity against 6A but having good activity against 6B and by the fact that anti-6B antibody concentrations needed for 50% killing of types 6B and 6A bacteria were substantially different.
In agreement with previous studies [4, 5, 8] , concentration and OPA of antibodies to the 6B strain correlated strongly with each other. The relationship between anti-6B concentration and OPA against the 6A strain was interesting; a considerable number of serum samples with an anti-6B concentration у1 mg/mL had no OPA to the 6A strain, whereas most of those serum samples had OPA to the 6B strain. We could not find any vaccine-specific differences in the correlations between anti-6B antibody concentration and OPA against the 6A strain. If in vitro OPA of antibodies to pneumococcal capsular polysaccharides is considered to be a correlate of their in vivo functional activity, anti-6B antibody concentrations might be useful at the individual level in predicting protection against 6B but not always against 6A strains. However, our data clearly show that the mean functional activity against the 6A strain was highest in the PncCRM group that also had the highest mean concentrations of anti-6B antibody. Thus we can conclude that, at the population level, the higher the anti-6B antibody response, the higher the protection also against 6A strains.
Our laboratory findings agree with the results of a Finnish efficacy trial of PncCRM vaccine, which was found to be 84% efficacious against acute otitis media caused by 6B strains, whereas its efficacy to acute otitis media caused by 6A strains was 57% [11] . The same vaccine has prevented invasive infections caused by 6A pneumococci [10] . However, in a South African study, 9-valent PncCRM reduced carriage of 6B but not of 6A pneumococci, which suggests that the cross-reactive protection may be different, depending on the nature of the infection [13] . These findings and the results of in vitro studies [4, 5] should be kept in mind when reevaluating whether to include type 6A PS into the future generations of multivalent conjugate vaccines. The accumulating data of finished and ongoing efficacy and immunogenicity trials hopefully can be used to find the serologic correlates or surrogates of protection not only to the vaccine serotypes but also to the cross-reactive types.
